Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy.

Venderink W, Bomers JG, Overduin CG, Padhani AR, de Lauw GR, Sedelaar MJ, Barentsz JO.

Eur Urol. 2019 Nov 29. pii: S0302-2838(19)30775-4. doi: 10.1016/j.eururo.2019.10.009. [Epub ahead of print]

2.

The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.

Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, Bosch JLHR, Barentsz JO, Somford DM, van Melick HHE.

Eur Urol. 2019 Apr;75(4):582-590. doi: 10.1016/j.eururo.2018.11.040. Epub 2018 Dec 3.

PMID:
30522912
3.

Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.

van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, van den Hout H, van der Lelij H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M, Hulsbergen-van de Kaa C, Barentsz JO.

Eur Urol. 2019 Apr;75(4):570-578. doi: 10.1016/j.eururo.2018.11.023. Epub 2018 Nov 23.

4.

Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.

Pokorny MR, de Rooij M, Duncan E, Schröder FH, Parkinson R, Barentsz JO, Thompson LC.

Eur Urol. 2014 Jul;66(1):22-9. doi: 10.1016/j.eururo.2014.03.002. Epub 2014 Mar 14.

PMID:
24666839
5.

Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy.

Kaufmann S, Russo GI, Bamberg F, Löwe L, Morgia G, Nikolaou K, Stenzl A, Kruck S, Bedke J.

World J Urol. 2018 May;36(5):761-768. doi: 10.1007/s00345-018-2189-7. Epub 2018 Jan 27.

PMID:
29380130
6.

Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.

Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, Vergunst H, Sedelaar JP, Fütterer JJ, Barentsz JO.

Eur Urol. 2012 Nov;62(5):902-9. doi: 10.1016/j.eururo.2012.01.047. Epub 2012 Feb 1.

PMID:
22325447
7.

Yield of Repeat Targeted Direct in-Bore Magnetic Resonance-Guided Prostate Biopsy (MRGB) of the Same Lesions in Men Having a Prior Negative Targeted MRGB.

Venderink W, Jenniskens SF, Michiel Sedelaar JP, Tamada T, Fütterer JJ.

Korean J Radiol. 2018 Jul-Aug;19(4):733-741. doi: 10.3348/kjr.2018.19.4.733. Epub 2018 Jun 14.

8.

Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.

Venderink W, van Luijtelaar A, Bomers JG, van der Leest M, Hulsbergen-van de Kaa C, Barentsz JO, Sedelaar JP, Fütterer JJ.

Eur Urol. 2017 Feb 28. pii: S0302-2838(17)30110-0. doi: 10.1016/j.eururo.2017.02.021. [Epub ahead of print]

PMID:
28258784
9.

Does magnetic resonance imaging-guided biopsy improve prostate cancer detection? A comparison of systematic, cognitive fusion and ultrasound fusion prostate biopsy.

Kam J, Yuminaga Y, Kim R, Aluwihare K, Macneil F, Ouyang R, Ruthven S, Louie-Johnsun M.

Prostate Int. 2018 Sep;6(3):88-93. doi: 10.1016/j.prnil.2017.10.003. Epub 2017 Nov 2.

10.

Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.

Hamoen EHJ, Hoeks CMA, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Bokhorst LP, Witjes JA, Rovers MM, Hulsbergen-van de Kaa CA, Barentsz JO.

Eur Urol Focus. 2019 May;5(3):407-415. doi: 10.1016/j.euf.2017.12.008. Epub 2018 Jan 10.

PMID:
29331622
11.

Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer.

Venderink W, van der Leest M, van Luijtelaar A, van de Ven WJM, Fütterer JJ, Sedelaar JPM, Huisman HJ.

World J Urol. 2017 Dec;35(12):1849-1855. doi: 10.1007/s00345-017-2085-6. Epub 2017 Sep 4.

12.

Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique?

Wegelin O, van Melick HHE, Hooft L, Bosch JLHR, Reitsma HB, Barentsz JO, Somford DM.

Eur Urol. 2017 Apr;71(4):517-531. doi: 10.1016/j.eururo.2016.07.041. Epub 2016 Aug 25. Review.

PMID:
27568655
13.

Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.

de Rooij M, Crienen S, Witjes JA, Barentsz JO, Rovers MM, Grutters JP.

Eur Urol. 2014 Sep;66(3):430-6. doi: 10.1016/j.eururo.2013.12.012. Epub 2013 Dec 21.

PMID:
24377803
14.

High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility.

van der Leest M, Israël B, Cornel EB, Zámecnik P, Schoots IG, van der Lelij H, Padhani AR, Rovers M, van Oort I, Sedelaar M, Hulsbergen-van de Kaa C, Hannink G, Veltman J, Barentsz J.

Eur Urol. 2019 Nov;76(5):574-581. doi: 10.1016/j.eururo.2019.05.029. Epub 2019 Jun 2.

15.

Cognitive-Targeted versus Magnetic Resonance Imaging-Guided Prostate Biopsy in Prostate Cancer Detection.

Osses DF, van Asten JJ, Tijsterman JD.

Curr Urol. 2018 Jun;11(4):182-188. doi: 10.1159/000447216. Epub 2018 Mar 30.

16.

MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature.

Pokorny M, Kua B, Esler R, Yaxley J, Samaratunga H, Dunglison N, Gianduzzo T, Coughlin G, Holt R, Laing B, Ault D, Brown N, Parkinson R, Thompson L.

World J Urol. 2019 Jul;37(7):1263-1279. doi: 10.1007/s00345-018-2497-y. Epub 2018 Sep 25. Review.

PMID:
30255394
17.

Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study.

Hoeks CM, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Roobol MJ, Bul M, Hambrock T, Witjes JA, Fütterer JJ, Hulsbergen-van de Kaa CA, Barentsz JO.

Invest Radiol. 2014 Mar;49(3):165-72. doi: 10.1097/RLI.0000000000000008.

PMID:
24220253
18.

Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.

Stabile A, Dell'Oglio P, Gandaglia G, Fossati N, Brembilla G, Cristel G, Dehò F, Scattoni V, Maga T, Losa A, Gaboardi F, Cardone G, Esposito A, De Cobelli F, Del Maschio A, Montorsi F, Briganti A.

Eur Urol Oncol. 2018 Jun;1(2):120-128. doi: 10.1016/j.euo.2018.02.002. Epub 2018 May 15.

PMID:
31100235
19.

Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?

Exterkate L, Wegelin O, Barentsz JO, van der Leest MG, Kummer JA, Vreuls W, de Bruin PC, Bosch JLHR, van Melick HHE, Somford DM.

Eur Urol Oncol. 2019 Jun 22. pii: S2588-9311(19)30080-X. doi: 10.1016/j.euo.2019.06.005. [Epub ahead of print]

PMID:
31239236
20.

Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition.

Engels RRM, Israël B, Padhani AR, Barentsz JO.

Eur Urol. 2019 Sep 30. pii: S0302-2838(19)30741-9. doi: 10.1016/j.eururo.2019.09.021. [Epub ahead of print]

Supplemental Content

Support Center